Communicating the benefits and harms of anticancer drugs
BMJ
.
2023 Mar 29:380:623.
doi: 10.1136/bmj.p623.
Authors
Timothy Feeney
1
,
Tiago Villanueva
2
,
Amy Price
2
Affiliations
1
The BMJ, London, UK tfeeney@bmj.com.
2
The BMJ, London, UK.
PMID:
36990503
DOI:
10.1136/bmj.p623
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antineoplastic Agents* / adverse effects
Communication*
Humans
Risk Assessment
Substances
Antineoplastic Agents